Tokyo, June 16, 2006 (JCN) - Kaneka has obtained positive results from preclinical trials for a drug eluting stent (DES) that it is currently developing. The Company commissioned Thoraxcenter, a hospital in the Netherlands, to conduct full-scale trials using pigs. The hospital confirmed that Kaneka’s DES effectively inhibits blood vessel inflammation and endothelial proliferation. Furthermore, the DES helps accelerate the healing of endothelium. Based on these findings, Kaneka expects that the DES may substantially reduce the risk of stent thrombosis.
